Received 14 May 1998/Returned for modification 30 June
1998/Accepted 21 September 1998
 |
INTRODUCTION |
The mdm2 oncogene was
originally identified as a gene that is amplified and overexpressed in
a tumorigenic derivative of mouse 3T3 cells (3T3DM), with the amplified
sequences being located on extrachromosomal double minute particles
(8). Subsequent studies revealed that overexpression of the
mdm2 gene was responsible for transformation of these cells
(19). Amplification and overexpression of the
mdm2 gene have been detected in a number of human sarcomas (41, 49), suggesting that this oncogene plays a role in
human carcinogenesis. The product of the mouse mdm2 gene is
a protein with a predicted molecular mass of 54 kDa, although it
migrates as a ~95-kDa protein in sodium dodecyl sulfate (SDS) gels
(4).
mdm2 associates with wild-type and certain mutant p53 proteins
(34, 47), and an excess of mdm2 can abrogate transcriptional activation by wild-type p53 (47). In addition, the binding
of mdm2 to p53 results in a decrease in p53 levels through enhanced degradation (33, 40) by a proteosome-mediated process
(40). Thus, overexpression of mdm2 serves as a negative
regulator of p53 function. The mdm2 gene is regulated by
wild-type p53 through an intronic sequence which contains a p53
DNA-binding region and functions as a p53 response element
(69). This results in an autoregulatory loop in which mdm2
complexes with p53, thereby reducing the extent of its own expression
(5, 67).
An interesting property of the mdm2 gene is that it can
generate multiple transcripts which may differ in coding potential. Sequence analysis of mdm2 clones isolated from murine
(19) and human (49) cDNA libraries indicates that
the mdm2 gene can generate at least seven distinct mRNA
species. The mdm2 splice variants differ in their ability to
inhibit p53-mediated transactivation (31). Thus, the
existence of multiple mdm2 proteins raises the possibility that mdm2
may elicit effects in cells independently of its known effect on p53.
This is suggested by studies indicating that mdm2 can overcome a
G1 cell cycle arrest mediated by members of the
retinoblastoma gene family (16, 68) and that expression of
mdm2 can activate E2F1/DP1 (46) and the cyclin A gene
promoter (44). This is also supported by studies of mdm2
expression in mammary tissue of p53+/+ and
p53
/
mice indicating that mdm2 can regulate DNA
synthesis independently of its ability to inhibit p53 activity. Recent
studies have also indicated that expression of mdm2 can be modulated by
factors other than p53 (e.g., fibroblast growth factor
[58]), suggesting that mdm2 may act and be regulated
independently of p53.
The thyroid hormones influence a variety of physiological processes,
including cell growth and metabolism in mammals, initiation of
metamorphosis in amphibia, and development of the vertebrate nervous
system (53). Most, if not all, of these actions are mediated
by thyroid hormone (L-triiodothyronine; T3) nuclear
receptors (T3Rs). The T3Rs are encoded by two genes (
and
) and
are expressed as several isoforms (T3R
1, T3R
1, and T3R
2)
(43). The T3Rs are members of the thyroid hormone/retinoid
receptor subfamily of nuclear hormone receptors, which includes the
retinoic acid receptors (RARs), the retinoid X receptors (RXRs),
the vitamin D receptor (VDR), the peroxisome proliferation
activation receptors (PPARs), and orphan receptors such as chicken
ovalbumin upstream promoter transcription factor (COUP-TF) (12,
24).
T3Rs activate transcription through DNA sequences referred to as
thyroid hormone response elements (TREs). Naturally occurring TREs are
organized as imperfect invert repeats and/or direct repeats (DRs) of
the optimized AGGTCA half-site (7, 63). TREs have been
identified in a wide variety of genes, including the long terminal
repeat (LTR) of Moloney murine leukemia virus (55), the
promoter and third intron of the rat growth hormone gene
(54), and the promoters of the malic enzyme (13)
and human
-myosin heavy-chain (62) genes, and within the
NF-
B motifs of the human immunodeficiency virus type 1 (HIV-1) LTR
(15). Certain TREs are also regulated by other members of
the T3R/RAR subfamily (e.g., the rat growth hormone TRE)
(62).
In this study, we report that T3R can stimulate the native
mdm2 gene in a T3-dependent fashion. Stimulation was found
to occur via a TRE(s) which we localized to the first intron of the
mdm2 gene. Similar results were found with homologous
sequences from the human mdm2 gene (70). In
contrast with T3R, no ligand-dependent stimulation was found with RAR,
RXR, VDR, or PPAR, although constitutive activation was found to occur
with COUP-TFI. Two T3R-responsive DNA elements were identified in the
mdm2 intron and further mapped to sequences within the
putative p53 binding sites. Our findings, which indicate that T3R can
regulate the mdm2 gene independently of p53, may provide an
explanation for certain known effects of T3 and T3R on cell
proliferation (22, 32) and in the promotion of tumor
development (29).
(This study was done by J.-S.Q. and Y.Y. in partial fulfillment of the
requirements for a Ph.D. degree from the Sackler Institute for Graduate
Biomedical Science at the New York University School of Medicine.)
 |
MATERIALS AND METHODS |
Cell culture and transfection.
HeLa cells and GH4C1 rat
pituitary cells were cultured and transfected by electroporation as
previously described (1, 22). p53-null (10)1 cells
(67) were transfected by calcium phosphate precipitation.
The chloramphenicol acetyltransferase (CAT) reporter vectors and other
plasmids used are described below. After incubation for 48 h with
or without the indicated ligand(s), cells were harvested for assay of
CAT activity by a thin-layer chromatography assay (1, 22).
Acetylated and unreacted [14C]chloramphenicol were
excised from the thin-layer plate and quantitated in a liquid
scintillation counter. The amount of protein used in the assays was
adjusted to keep the percent conversion of
[14C]chloramphenicol below 40%, which is in the linear
range. CAT activity values were normalized to represent the percentage
of [14C]chloramphenicol acetylated by a specific amount
of cell protein in 16 h at 37°C. All experiments were performed
with duplicate or triplicate flasks, which showed variations of less
than 10%, and each experiment was repeated at least three times with
similar results.
Cloning and plasmid construction.
The full-length chicken
T3R
(cT3R
) cDNA corresponding to amino acids 1 to 408, cloned
into a pEXPRESS (pEX) vector (pEX-cT3R
), has been described
previously (25). pRSVT7-cT3R
(21-408),
pEX-cT3R
(31-408), pEX-cT3R
(51-408),
pRSV-T7-cT3R
(21-30/51-408), and pRSV-T7-cT3R
(13-20/51-408) have been described previously (14, 30, 57). Human T3R
1 (hT3R
1) (28) and rat T3R
2 (rT3R
2) (35)
were also expressed from pEX vectors. Wild-type and mutant human p53
plasmids, pC53-SN3 and pC53(V143A) (gifts from Bert Vogelstein),
respectively, utilize a pCMV-Neo-Bam vector (3) or a T7
polymerase-transcribed pBluescript vector. The 59-nucleotide murine p53
response element sequence (TGGTCAAGTTGGGACACGTCCggcgtcggctgtcggagGAGCTAAGTCCTGACATGTCT
[uppercase corresponds to Seq1 and Seq2]) from the first intron
of the murine mdm2 gene (67) was cloned into the
HindIII site at position
88 of
MTV-CAT, which lacks
the glucocorticoid response elements of the mouse mammary tumor virus
LTR (63). This vector has been termed
MTV-m59-CAT.
5'-TGGTCAAGTTGGGACACGTCC-3' (Seq1) and
5'-GAGCTAAGTCCTGACATGTCT-3' (Seq2) from the 59-bp element
were cloned upstream of nucleotide
88 in
MTV-CAT and have been
termed
MTV-Seq1-CAT and
MTV-Seq2-CAT, respectively. The
homologous 59-bp p53 response element from the human mdm2
gene (70) was also cloned at position
88 of
MTV-CAT (
MTV-h59-CAT). Cosx1CAT, which contains a 1-kb fragment from the
first intron of the murine mdm2 gene subcloned upstream from the adenovirus major late TATA box-terminal deoxynucleotidyltransferase (TdT) initiation signal-CAT gene sequence (p1634CAT) (67),
was a gift from Arnold J. Levine. Various deletion mutants containing different fragments of the mdm2 first-intron region cloned
into the p1634CAT vector (H0.5
NCAT, HX0.5CAT, BN300CAT, BA200CAT, and BP100CAT) (67) were also generously provided by Arnold
J. Levine. A COUP-TFI-expressing Rous sarcoma virus vector that has been described elsewhere (11) was obtained from Ming-Jer Tsai.
Gel mobility shift assays.
cT3R
was expressed in
Escherichia coli and purified to apparent homogeneity as
described previously (23). Following the purification, the
amount of cT3R
was estimated with
L-[125I]T3 (23). Double-stranded
oligonucleotides complementary to Seq1 and Seq2, as mentioned above,
were synthesized and annealed. These oligonucleotides are flanked by
HindIII cohesive ends, permitting cloning and end
labeling. cT3R
was incubated with 32P-labeled Seq1 or
Seq2 as described previously (23). The 30-µl incubation
mixture contained 25 mM Tris (pH 7.8), 0.5 mM EDTA, 80 mM KCl, 1 mM
dithiothreitol, 100 ng of aprotinin, 0.25 µg of poly(dI-dC), 0.05%
(vol/vol) Triton X-100, 10% (vol/vol) glycerol, and various amounts of
receptor, with or without 1 µM T3. For studies involving heterodimer
binding to Seq1, the incubation mixture contained 15 fmol of
reticulosyte lysate-synthesized cT3R
and 25 fmol of
baculovirus-expressed murine RXR
(mRXR
) as previously described
(1). Samples were analyzed by electrophoresis at 4°C in
nondenaturing SDS-5% polyacrylamide gels in buffer containing 10 mM
Tris, 7.5 mM acetic acid, and 40 µM EDTA (pH 7.8) (23). The gels were dried and autoradiographed.
Western blot analysis of mdm2.
GH4C1 cells were cultured in
hormone-depleted medium (22) for 24 h. The cells were
then incubated with 500 nM T3 for 4 days, 2 days, or 1 day before the
cells were harvested for assay of mdm2. Some cells were incubated
without T3 for the 4-day period. At the time of harvest, the cells were
about 70 to 80% confluent. Cells were then washed twice with
phosphate-buffered saline, scraped from the dishes, and lysed in RIPA
buffer (50 mM Tris-HCl [pH 7.5], 5 mM EDTA [pH 8.0], 0.5% Nonidet
P-40, 0.5% deoxycholic acid, 0.1% SDS, 150 mM NaCl), supplemented
with 1 mM phenylmethylsulfonyl fluoride, 1 µg of aprotinin per ml, 2 µg of leupeptin per ml, and 1 µg of pepstatin per ml, for 30 min on
ice with frequent vortexing. Lysates were then clarified by
microcentrifugation, and a small aliquot of each was removed for
determination of the protein concentration. Equal quantities of lysate
protein were separated in an SDS-10% polyacrylamide gel. Verification
of the efficiency of transfer to nitrocellulose and the equality of
loaded protein quantities were determined by staining the membrane with 0.5% Ponceau S in 10% acetic acid and by probing the blots with antiactin antibody. Blots were washed in H2O and then
incubated overnight at 4°C in blocking buffer (5% nonfat dry milk in
Tris-buffered saline [TBS]) and then with anti-mdm2 monoclonal
antibody 2A10 (a gift from Arnold J. Levine), which recognizes the
central region (amino acids 294 to 339) of hmdm2 and reacts with mdm2
proteins from a variety of species. Blots were also probed with a
monoclonal antibody (Ab-1; Oncogene Science) that recognizes only the N
terminus of mdm2. Blots were washed four times with TBS supplemented
with Triton X-100 and then twice with unsupplemented TBS. Blots were then incubated at room temperature for 1 h with peroxidase-labeled goat anti-mouse immunoglobulin G second antibody (Kirkegaard & Perry
Laboratories, Inc.) at 0.2 µg/ml, washed four times with TBS, and
then visualized with an enhanced chemiluminescence detection system
(E. I. Dupont de Nemours & Co.).
 |
RESULTS |
The mdm2 gene is stimulated by T3 in GH4C1 cells.
T3 is known to stimulate the growth of GH4C1 cells and related rat
pituitary cell lines which express T3Rs (9, 22). This growth-stimulatory effect of T3 has been shown to result from an effect
on the G1 phase of the cell cycle (32). Since
these cells express functional p53 (52), and p53 is known to
influence the length of G1, we assessed whether T3 might
act to inhibit p53-mediated responses in GH4C1 cells. Since the
expression of mdm2 is a sensitive indicator of p53 activity, we studied
the effect of T3 on mdm2. Western blotting studies indicate that GH4C1 cells express three forms of mdm2 which range from 85 to 95 kDa (Fig.
1). This is consistent with previous
reports indicating that the mdm2 gene encodes a number of
alternatively spliced mRNAs that give rise to several isoforms of mdm2
protein in the cell (31, 50). The mdm2 isoforms,
particularly the 85-kDa form, were stimulated rather than inhibited by
T3, suggesting that T3R acts indirectly (i.e., via p53) or directly to
activate the mdm2 gene.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 1.
The mdm2 gene is stimulated by T3 in GH4C1
cells. GH4C1 cells were cultured in hormone-depleted medium (22,
27) for 24 h. The cells were then incubated with (+) or
without ( ) 500 nM T3 for 4 days, 2 days, or 1 day before the cells
were harvested for assay of mdm2. Day 0 cells were incubated without T3
for the entire 4-day period. Equal quantities of cell lysate protein
were separated in an SDS-10% polyacrylamide gel. After transfer to
nitrocellulose membranes, the samples were blotted with anti-mdm2
monoclonal antibody 2A10, which recognizes the central region of the
mdm2 protein.
|
|
The first intron of the mdm2 gene contains a
ligand-dependent TRE.
The first intron of the mdm2 gene
contains a p53 binding site which, when placed upstream of a minimal
promoter, can stimulate a reporter gene in a p53-dependent fashion
(38, 67). To determine whether T3R regulates mdm2 without
indirectly affecting p53, T3-dependent stimulation of Cosx1CAT was
analyzed in HeLa cells, which express very little if any p53
(56). Cosx1CAT contains a 1-kb DNA fragment from the first
intron of the mdm2 gene cloned just upstream of the
adenovirus major late TATA box and TdT initiator sequence which is
linked to the CAT reporter gene (67). HeLa cells were transfected with Cosx1CAT with or without vectors expressing cT3R
. T3 stimulated expression of Cosx1CAT about 15-fold (Fig.
2). Expression of the control
minimal-promoter CAT reporter gene, which lacks the 1-kb
mdm2 intronic region (p1634CAT) (not shown), was not altered
by T3. This suggests that T3R can activate the mdm2 gene independently of p53 and that the first intron of the mdm2
gene contains a response element(s) for T3R in addition to a response element(s) for p53.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 2.
The first intron of the mdm2 gene contains a
T3-dependent response element. HeLa cells were transfected by
electroporation with 5 µg of Cosx1CAT or the indicated deletion
mutants of Cosx1CAT with 4 µg of a vector expressing cT3R .
Cosx1CAT contains a 1-kb XhoI-XhoI fragment from
the first intron of the murine mdm2 gene cloned upstream
from the adenovirus major late TATA box-TdT initiation signal-CAT gene
sequence (67). Following transfection, cells were incubated
for 48 h without or with 500 nM T3 prior to determination of CAT
activity.
|
|
The mdm2 TRE is embedded within the p53-responsive sequence.
The TRE within the mdm2 gene was mapped to an 85-bp
HincII-PvuII sequence in the first intron of
mdm2 (Fig. 2). T3-dependent stimulation by cT3R
was found
only with constructs containing this 85-bp sequence, which has been
reported to also contain the p53 response element of the gene
(67). To further map the TRE, a 59-bp putative p53 response
sequence (Fig. 3) from the 85-bp HincII-PvuII region of the murine mdm2
gene was cloned at nucleotide
88 of
MTV-CAT to create
MTV-m59-CAT. This 59-bp sequence can be divided into two regions
(Seq1 and Seq2) (Fig. 3), which were individually cloned at position
88 of
MTV-CAT, resulting in
MTV-Seq1-CAT and
MTV-Seq2-CAT,
respectively. Underlined in Seq1 and Seq2 of Fig. 3 are hexanucleotide
sequences which show a high degree of homology to those found in known
TREs (6, 10, 15).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 3.
Nucleotide sequences of Seq1 and Seq2 of the 59-bp
intronic p53 response element of the mdm2 gene. Underlined
are hexanucleotide sequences showing a high degree of homology to known
native TREs, suggesting that the TRE in Seq1 is organized as a DR+4
TRE. The sequence underlined in Seq2 has on its complementary strand
AGGACT. This is identical to sequences found in a TRE from
the human thyroid-stimulating hormone gene (10) and from
the TRE sequences at positions 88 to 83 and 102 to 97 of the
NF- B binding sites of the HIV-1 LTR (15).
|
|
T3 and cT3R
strongly stimulated
MTV-m59-CAT and
MTV-Seq1-CAT
in HeLa cells but only weakly activated
MTV-Seq2-CAT (Table 1). These results suggest that Seq1
contains a strong TRE while Seq2 contains a weak TRE. Stimulation of
Seq1 by T3 was similar to that found with
MTV-TREp-CAT, which
contains an optimized TRE (TREp; AGGTCA TGACCT)
(Table 1). The
MTV-m59-CAT reporter gene was also strongly
stimulated by wild-type p53. p53 or cT3R
activated
MTV-Seq1-CAT
to the same extent as
MTV-m59-CAT, while
MTV-Seq2-CAT was much
less efficiently activated by p53 or cT3R
(Table 1). None of these
plasmids showed significant CAT expression without expression of p53 or
cT3R
, which is consistent with the notion that HeLa cells contain
very low levels of p53 (56) and T3R (23). Our
findings are consistent with the prior prediction that the 59-bp
sequence of the mdm2 gene's first intron contains two
putative p53 binding sites (Seq1 and Seq2) (38, 67).
However, our results indicate that these two sites can function
independently and that the 5' site (Seq1) functions more efficiently as
a p53 response element than the 3' site (Seq2). The similar relative extents of activation of
MTV-m59-CAT,
MTV-Seq1-CAT, and
MTV-Seq2-CAT by p53 and T3R suggest that these factors interact with
similar sequences contained within Seq1 or Seq2.
To assess whether the human mdm2 p53 response element is also T3R
responsive, we cloned the homologous 59-bp fragment from the human gene
into
MTV-CAT and examined activation of the resulting constructs,
MTV-m59-CAT and
MTV-h59-CAT, by the T3R isoforms cT3R
,
hT3R
1, and rT3R
2 as well as by p53 (Table
2).
MTV-m59-CAT and
MTV-h59-CAT
were similarly activated by cT3R
, hT3R
1, and rT3R
2, while the
response to p53 was slightly greater for
MTV-h59-CAT. This slight
increase in response of human mdm2 to p53 was a consistent finding.
Although the T3Rs can stimulate the 59-bp mdm2 sequence in
HeLa cells, these cells may express low levels of p53. To determine whether T3R can stimulate the 59-bp mdm2 sequence
independently of an action of p53, we studied the effect of T3Rs on
stimulation of
MTV-m59-CAT in (10)1 cells which express no p53
(67) (Table 3).
MTV-m59-CAT
was stimulated by p53 as well as by cT3R
or hT3R
1 in the presence
of T3. In the absence of T3, cT3R
or hT3R
1 inhibited stimulation
by p53, supporting the notion that p53 and the T3Rs may bind to the
same or overlapping sequences. Similar studies with p53-null SAOS-2
cells also documented T3-dependent activation of
MTV-m59-CAT (data
not shown).
To assess whether the mdm2-responsive sequence is activated by
endogenously expressed p53 or T3R, GH4C1 cells were transfected with
MTV-m59-CAT,
MTV-TREp-CAT, or
MTV-CAT (Table
4). As found in HeLa cells (Tables 1 and
2), very low levels of basal expression were evident for
MTV-TREp-CAT and
MTV-CAT. However, in contrast with the results
for HeLa cells, high levels of basal activity was found with
MTV-m59-CAT (Table 4), which is consistent with previous studies
indicating that GH4C1 cells contain functional p53 (52).
Addition of T3 resulted in further activation of
MTV-m59-CAT by
endogenous T3R and a similar stimulation of
MTV-TREp-CAT but no
stimulation of
MTV-CAT (Table 4). These results, along with the
findings for HeLa cells and (10)1 cells (Tables 1 to 3), support the
notion that endogenous T3Rs in GH4C1 cells (26, 27) can
activate the mdm2 gene through the same intronic 59-bp p53-responsive sequence.
T3R binds to Seq1 and Seq2 of the p53-responsive element.
TREs
of native genes are organized as DRs and/or inverted repeats of
hexanucleotide half-sites separated by variously sized nucleotide gaps
(6, 48, 64). The half-site sequences of native genes show
significant diversity, indicating that the T3Rs are capable of
activating a wide variety of structurally divergent TREs. To study the
binding of T3R to the 59-bp sequence of the murine element, gel
mobility shift assays were performed with 32P-labeled Seq1
or Seq2 as the probe. cT3R
bound to both Seq1 and Seq2 as monomers
and homodimers, but it exhibited a higher degree of affinity for Seq1
(Fig. 4A and B). T3 increased the binding
of monomers but decreased the binding of homodimers to both sequences
(Fig. 4A and B). This effect of T3 is commonly seen with DR elements,
suggesting that the Seq1 and Seq2 TREs have such an organization. T3Rs
bind preferentially to DNA as heterodimers with the RXRs in vitro, and
we and others have provided evidence that the T3R-RXR heterodimer is
the functional form of the receptor on most native response elements in
vivo (1, 51). The ability of cT3R
and mRXR
to bind as
a heterodimer to Seq1 and Seq2 was studied. cT3R
and mRXR
bound
as an abundant heterodimer to Seq1 (Fig. 4C), while the extent of
heterodimer binding to Seq2 was very low (not illustrated), which
paralleled the functional activity of T3-dependent stimulation of these
sequences (Table 1).

View larger version (68K):
[in this window]
[in a new window]

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 4.
Binding of T3R to Seq1 and Seq2 of the mdm2 p53 response
sequence. Gel mobility shift assays were used to study the binding of
purified cT3R , at 15 (+), 30 (++), or 45 (+++) fmol, to
32P-labeled Seq1 (A) or Seq2 (B) in the absence ( ) or
presence (+) of 1 µM T3. Shifted complexes are indicated by arrows.
(C) Binding of 15 fmol of cT3R plus 25 fmol of mRXR . For the
experiment in panel C, the cT3R used was synthesized in vitro, using
rabbit reticulocyte lysate (2 µl) (1), while mRXR was
synthesized by using a baculovirus (bv) expression vector
(45). Two microliters of unprogrammed reticulocyte lysate
was used as a control. The migration positions of cT3R monomers,
homodimers, and cT3R -mRXR heterodimers have been previously
established (1, 23).
|
|
A 10-amino-acid sequence in the A/B region of T3R
, which is
important for interaction with TFIIB, is also required for activation
of mdm2.
The domain structures of cT3R
and p53 are illustrated
in Fig. 5. The N-terminal A/B region is
the least-conserved region among members of the thyroid/retinoid
receptor subfamily and the T3R isoforms. The highly conserved
68-amino-acid C domain is organized into two zinc finger DNA-binding
structures. High-affinity ligand binding requires the D, E, and F
domains, a region which also contains the
i and heptad repeats
thought to be involved in protein-protein interactions (1, 24,
51). Amino acids 21 to 30 (DGKRKRKSSQ), in the A/B region,
contain a cluster of five basic amino acids important for
transcriptional activation of native TREs and for interaction with the
general transcription factor TFIIB (30). This 10-amino-acid
sequence also appears to be important for activation via the
mdm2 intronic TRE (Fig. 6).
Several N-terminal deletion mutants of cT3R
were compared for their
ability to transactivate Cosx1CAT. Transfection studies indicate that
cT3R
(21-408), but not cT3R
(31-408), activated Cosx1CAT
similarly to wild-type cT3R
(Fig. 6). These results indicate that
amino acids 21 to 31 are required for transcriptional stimulation by
the mdm2 intronic TRE and that TFIIB likely plays a role in
this activation. This was further confirmed by functional studies
indicating that cT3R
(21-30/51-408), but not
cT3R
(13-20/51-408), can stimulate Cosx1CAT (Fig. 6).

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 5.
Domain structures of cT3R (A) and p53 (B). (A)
cT3R , like other members of the nuclear receptor family, can be
divided into six distinct regions (A to F) (18). The
N-terminal A/B region is the least-conserved region among the nuclear
hormone receptors. The highly conserved 68-amino-acid C domain (amino
acids 51 to 119) is organized into two zinc finger DNA-binding
structures. D, E, and F comprise the ligand-binding domain (amino acids
120 to 408) (37). (B) p53 can be divided into three regions.
The N terminus (amino acids 1 to 43) contains a strong transcription
regulatory region (20, 61, 69) and interacts with a number
of proteins, including mdm2 (39). The central region (amino
acids 100 to 300) contains the sequence-specific DNA-binding domain
(69) and four regions (II to V) that are evolutionarily
conserved within all vertebrate species (59). The C-terminal
region contains an oligomerization domain that dictates the formation
of stable p53 tetramers (amino acids 340 to 393) (60) and a
nonspecific nucleic acid-binding domain (amino acids 330 to 393)
(66).
|
|

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 6.
A 10-amino-acid sequence in the N-terminal A/B domain of
cT3R is required for activation of the mdm2 TRE. HeLa cells were
transfected by electroporation with 5 µg of Cosx1CAT alone or with 4 µg of vector expressing wild-type cT3R or the indicated N-terminal
deletion mutants of cT3R . Following transfection, cells were
incubated for 48 h without or with 500 nM T3 prior to
determination of CAT activity.
|
|
The mdm2 p53/T3R response element is also activated by COUP-TFI but
not by RAR, VDR, RXR, or PPAR.
COUP-TFI was initially
characterized by its binding to the COUP element (positions
90 to
70) (2, 65). Analysis of COUP-TFI binding sites revealed
that COUP-TF could bind to many A/GGGTCA repeats with different
spacings and orientations (12). COUP-TFI is known to repress
hormonal induction of many target genes by VDR, T3R, and RAR
(11). Transfer of the putative ligand binding domain of
COUP-TFI to the GAL4 DNA binding domain suggested that it possesses an
active silencing function within its C-terminal domain (11).
To determine whether COUP-TFI had an effect on the transcriptional
regulation of Cosx1CAT, HeLa cells were transfected with Cosx1CAT with
or without a vector expressing COUP-TFI. Surprisingly, CAT activity was
stimulated rather than repressed by COUP-TFI (Fig.
7). COUP-TFI stimulation was localized to
the same 85-bp p53/T3R response region (Fig. 7), indicating that
COUP-TFI, which normally represses many promoters, can also function as
a transcriptional activator on specific response sequences. In contrast
with T3R and COUP-TFI, hRAR
, hVDR, hRXR
, and hPPAR
did not
stimulate Cosx1CAT without or with their cognate ligands (data not
shown).

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 7.
COUP-TFI activates the mdm2 p53 response sequence. HeLa
cells were transfected by electroporation with 4 µg of the indicated
reporters that contain different fragments of the first intron of the
mdm2 gene and 4 µg of a pRSV control vector ( COUPTFI) or
pRSV-COUP-TFI (+COUPTFI). Following transfection, cells were incubated
in hormone-depleted medium for 48 h prior to determination of CAT
activity.
|
|
 |
DISCUSSION |
Previous studies have shown that p53 stimulates the expression of
the mdm2 gene through a p53 response sequence in the first intron of the mdm2 gene (38, 67). The segment
conferring p53 responsiveness includes two elements which display
significant homology to a consensus p53 binding site (17).
These two elements have been termed Seq1 and Seq2 (Fig. 3). We showed
that the 59-bp p53 DNA-binding site contains two TREs (Table 1) and
that the major TRE in the 59-bp region is contained within Seq1. T3R
binds as a monomer or homodimer with a higher affinity for Seq1 than for Seq2 (Fig. 4A and B), or it binds to Seq1 as a heterodimer with
RXR. This difference in affinity for T3R parallels the difference in
the abilities of Seq1 and Seq2 to function as TREs (Table 1). The
strong TRE found in Seq1 resembles a DR with a 4-bp gap (DR+4), which
is characteristic of many native TREs (Fig. 3). Inspection of Seq1
indicates that it contains the sequence TGGTCAagttGGGACA, which resembles an idealized TRE half-site (AGGTCA)
organized as an imperfect DR with a 4-bp gap (DR+4). Examination
of Seq2 indicated that it contains the sequence AGTCCT. The
half-site on the complementary strand (AGGACT) is identical
to half-sites found in a TRE from the human thyroid-stimulating hormone
gene (10) and in the TRE sequences at positions
88 to
83 and
102 to
97 of NF-
B binding sites of the HIV-1 LTR
(15).
Activation by wild-type p53 parallels the findings with T3R (i.e., the
59-bp fragment containing Seq1 and Seq2 is about as active as that
containing only Seq1, and both are much more active than that
containing only Seq2) (Table 1). This suggests that T3R and p53 may
contact similar sequences in the 59-bp mdm2 sequence. This
is further supported by the finding that expression of unliganded T3R
blocks p53-mediated stimulation of
MTV-m59-CAT (Table 3). All
isoforms of T3R activate the mdm2 response sequence as well as the homologous sequence from the human mdm2 gene (Table
2). Hadzic et al. (30) showed that amino acids 21 to 30 (DGKRKRKSSQ) in the A/B region of cT3R
contain a cluster of five
basic amino acids that are important for transcriptional activation of
native TREs and for interaction with the general transcription factor TFIIB. Similarly, this 10-amino-acid region was also found to be
important for transcriptional activation of Cosx1CAT. The related receptors hRAR
, hRXR
, hPPAR
, and hVDR do not transcriptionally activate these sequences, which is consistent with the apparent DR+4
organization of the TRE. In contrast, the orphan receptor COUP-TF,
which commonly represses the activity of TREs, activates the mdm2
response sequence in Cosx1CAT (Fig. 7).
The mdm2 protooncogene is amplified in a variety of tumors
and approximately 30% of sarcomas (41, 49). Overexpression of mdm2 inhibits the prolongation or blockade of
G1 progression mediated by p53 as well as the ability of
p53 to suppress transformation of cells in culture (21).
Although the action of mdm2 as an oncogene could occur
solely by inhibiting the function of p53 (4, 67), it could
also function through p53-independent pathways. This is supported by
recent studies indicating that mdm2 can overcome the G1
cell cycle arrest mediated by members of the retinoblastoma gene family
(16, 68) and that expression of mdm2 can activate E2F1/DP1
(46) and the cyclin A gene promoter (44). The
mdm2 gene encodes a number of alternatively spliced mRNAs
that give rise to multiple protein forms (31, 50). Some
isoforms lack the N-terminal epitopes required for the mdm2-p53
interaction (31, 50), which further implies a function for
mdm2 in addition to its ability to block p53-mediated responses.
Landers et al. (42) found that high levels of mdm2 proteins
are present in two choriocarcinoma cell lines that also overexpress wild-type p53. In this study, we found that GH4C1 cells, which appear
to express functional p53 (Table 4), express high levels of mdm2 (Fig.
1). GH4C1 cells express T3R
1, T3R
1, and T3R
2 (36).
Several forms of mdm2, particularly the ~85-kDa form, were found to
be stimulated by endogenous T3Rs when GH4C1 cells were treated with T3
(Fig. 1). This ~85-kDa form of mdm2 was not detected with monoclonal
antibody Ab-1 (Oncogene Science), which recognizes the N terminus of
mdm2 (data not shown), suggesting that the ~85-kDa form of mdm2 does
not possess the N-terminal amino acid sequence required for interaction
with p53. This suggests that the ~85-kDa form of mdm2 may mediate
functions of mdm2 independently of its ability to block p53-mediated
functions. Our results do not document that the regulation of mdm2 by
T3R is through a direct pathway, because it takes at least 24 h to
detect the stimulation (Fig. 1). However, one possible mechanism to
account for the lag period in a direct activation pathway is that the
mdm2 stimulated by T3 binds with endogenous p53, which in turn acts to
decrease p53-mediated mdm2 stimulation (4, 67). This
reduction in mdm2 stimulation by p53 offsets the initial extent of
stimulation by T3R, resulting in an apparent lag in the time until
stimulation by T3 is detected. This is consistent with the finding that
endogenous levels of mdm2 appear to be sufficient to regulate p53
levels and that increased expression of mdm2 can reduce the level of p53 (40).
Our results also indicate that p53 independently transactivates Seq1
and Seq2 (Table 1), consistent with the prediction that both Seq1 and
Seq2 resemble a p53 consensus sequence (4, 67). Interestingly, activation by Seq1 is similar to that found for the
entire 59-bp response sequence, suggesting that Seq1 predominantly contributes to the response of the mdm2 element to p53. In addition, p53 and T3R appear to compete for the same or overlapping DNA sequences
(Table 3). These results are consistent with a model in which T3R
regulates the mdm2 gene, particularly in cells that lack or
contain low levels of p53 or contain p53 mutants deficient in DNA
binding. Mutations in the DNA binding region of p53 are common in human
cancer, and the wild-type p53 allele is often concomitantly deleted.
Our findings suggest that under these conditions, T3R or related
factors such as COUP-TF may act to regulate the mdm2 gene.
Such stimulation would also occur in cells containing levels of
endogenous p53 which only partially compete with T3R or COUP-TF for the
mdm2 gene-responsive sequence. This notion is supported by
the finding that endogenous T3R can further activate
MTV-m59-CAT in
the presence of endogenous levels of p53 in GH4C1 cells (Table 4). The
regulation of mdm2 by T3R and COUP-TF, as well as other,
as-yet-undefined transcription factors, may provide a mechanism for the
growth-promoting effects of the T3Rs or other factors on certain cell
types as well as for the mdm2-mediated development of tumors in cells
containing p53 mutants or low levels of p53.
We thank A. J. Levine for Cosx1CAT, the Cosx1CAT deletion
mutants, the p1634CAT vector control, monoclonal antibody 2A10 against human and rodent mdm2, and p53-null (10)1 cells. We also thank B. Vogelstein for vectors expressing wild-type human p53.
This research was supported by NIH grant DK16636 to H.H.S. During this
work, V.D.-Y. was an Aaron Diamond Foundation fellow (grant
HRI817-5332F), and this work was supported in part by The Aaron Diamond
Foundation. Oligonucleotide synthesis was provided by the NYUMC General
Clinical Research Center (NIH NCRR grant M01RR00096). H.H.S. and
V.D.-Y. are members of the NYUMC Cancer Center (funded by grant
CA16087). Sequence analysis and database searches were through the
NYUMC Research Computing Resource, which received support from the
National Science Foundation (grant DIR-8908095).
| 1.
|
Au-Fliegner, M.,
E. Helmer,
J. Casanova,
B. M. Raaka, and H. H. Samuels.
1993.
The conserved ninth C-terminal heptad in thyroid hormone and retinoic acid receptors mediates diverse responses by affecting heterodimer but not homodimer formation.
Mol. Cell. Biol.
13:5725-5737[Abstract/Free Full Text].
|
| 2.
|
Bagchi, M. K.,
S. Y. Tsai,
M.-J. Tsai, and B. W. O'Malley.
1987.
Purification and characterization of chicken ovalbumin gene upstream promoter transcription factor from homologous oviduct cells.
Mol. Cell. Biol.
7:4151-4158[Abstract/Free Full Text].
|
| 3.
|
Baker, S. J.,
S. Markowitz,
E. R. Fearon,
J. K. U. Willson, and B. Vogelstein.
1990.
Suppression of human colorectal carcinoma cell growth by wild-type p53.
Science
249:912-915[Abstract/Free Full Text].
|
| 4.
|
Barak, Y. T.,
T. Juven,
R. Haffner, and M. Oren.
1993.
mdm2 expression is induced by wild type p53 activity.
EMBO J.
12:461-468[Medline].
|
| 5.
|
Barettino, D.,
T. H. Bugge,
P. Bartunek,
M. V. Ruiz,
V. Sonntag-Buck,
H. Beug,
M. Zenke, and H. G. Stunnenberg.
1993.
Unliganded T3R, but not its oncogenic variant, v-erbA, suppresses RAR-dependent transactivation by titrating out RXR.
EMBO J.
12:1343-1354[Medline].
|
| 6.
|
Brent, G. A.,
J. W. Harney,
Y. Chen,
R. L. Warne,
D. D. Moore, and P. R. Larsen.
1989.
Mutations of the rat growth hormone promoter which increase and decrease response to thyroid hormone define a consensus thyroid hormone response element.
Mol. Endocrinol.
3:1996-2004[Abstract].
|
| 7.
|
Brent, G. A.,
P. R. Larsen,
J. W. Harney,
R. J. Koenig, and D. D. Moore.
1989.
Functional characterization of the rat growth hormone promoter elements required for induction by thyroid hormone with and without a co-transfected beta type thyroid hormone receptor.
J. Biol. Chem.
264:178-182[Abstract/Free Full Text].
|
| 8.
|
Cahilly-Snyder, L.,
T. Yang-Feng,
U. Francke, and D. L. George.
1987.
Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line.
Somat. Cell Mol. Genet.
13:235-244[Medline].
|
| 9.
|
Casanova, J.,
Z. D. Horowitz,
R. P. Copp,
W. R. McIntyre,
A. Pascual, and H. H. Samuels.
1984.
Photoaffinity labeling of thyroid hormone nuclear receptors: influence of n-butyrate and analysis of the half-lives of the 57,000 and 47,000 molecular weight receptor forms.
J. Biol. Chem.
259:12084-12091[Abstract/Free Full Text].
|
| 10.
|
Chatterjee, V. K. K.,
J.-K. Lee,
A. Rentoumis, and J. L. Jameson.
1989.
Negative regulation of the thyroid stimulating hormone alpha gene by thyroid hormone: receptor interaction adjacent to the TATA box.
Proc. Natl. Acad. Sci. USA
86:9114-9118[Abstract/Free Full Text].
|
| 11.
|
Cooney, A. J.,
X. Leng,
S. Y. Tsai,
B. W. O'Malley, and M.-J. Tsai.
1993.
Multiple mechanisms of chicken ovalbumin upstream promoter transcription factor-dependent repression of transactivation by the vitamin D, thyroid hormone, and retinoic acid receptors.
J. Biol. Chem.
268:4152-4160[Abstract/Free Full Text].
|
| 12.
|
Cooney, A. J.,
S. Y. Tsai,
B. W. O'Malley, and M.-J. Tsai.
1992.
Chicken ovalbumin upstream promoter transcription factor (COUP-TF) dimers bind to different GGTCA response elements, allowing COUP-TF to repress hormonal induction of the vitamin D3, thyroid hormone, and retinoic acid receptors.
Mol. Cell. Biol.
12:4153-4163[Abstract/Free Full Text].
|
| 13.
|
Deavergne, B.,
K. J. Petty, and V. M. Nikodem.
1991.
Functional characterization and receptor binding studies of the malic enzyme thyroid hormone response element.
J. Biol. Chem.
266:1006-1013.
|
| 14.
|
Desai-Yajnik, V.,
E. Hadzic,
P. Modlinger,
S. Malhotra,
G. Gechlik, and H. H. Samuels.
1995.
Interactions of thyroid hormone receptor with the human immunodeficiency virus type 1 (HIV-1) long terminal repeat and the HIV-1 Tat transactivator.
J. Virol.
69:5103-5112[Abstract].
|
| 15.
|
Desai-Yajnik, V., and H. H. Samuels.
1993.
The NF- B and Sp1 DNA motifs of the human immunodeficiency virus type 1 long terminal repeat function as novel thyroid hormone response elements.
Mol. Cell. Biol.
13:5057-5069[Abstract/Free Full Text].
|
| 16.
|
Dubs-Poterszman, M. C.,
B. Tocque, and B. Wasylyk.
1995.
MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest.
Oncogene
11:2445-2449[Medline].
|
| 17.
|
El-Deiry, W. S.,
S. E. Kern,
J. A. Pietenpol,
K. W. Kinzler, and B. Vogelstein.
1992.
Human genomic DNA sequences define a consensus binding site for p53.
Nat. Genet.
1:44-49.
|
| 18.
|
Evans, R. M.
1988.
The steroid and thyroid hormone receptor superfamily.
Science
240:889-895[Abstract/Free Full Text].
|
| 19.
|
Farkharzadeh, S. S.,
S. P. Trusko, and D. L. George.
1991.
Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.
EMBO J.
10:1565-1569[Medline].
|
| 20.
|
Fields, S., and S. K. Jang.
1990.
The p53 proto-oncogene can act as a suppressor of transformation.
Science
249:1046-1049[Abstract/Free Full Text].
|
| 21.
|
Finlay, C. A.
1993.
The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.
Mol. Cell. Biol.
13:301-306[Abstract/Free Full Text].
|
| 22.
|
Flug, F.,
R. P. Copp,
J. Casanova,
Z. D. Horowitz,
L. Janocko,
M. Plotnick, and H. Samuels.
1987.
cis-acting elements of the rat growth hormone gene which mediate basal and regulated expression by thyroid hormone.
J. Biol. Chem.
262:6373-6382[Abstract/Free Full Text].
|
| 23.
|
Forman, B. M.,
J. Casanova,
B. M. Raaka,
J. Ghysdael, and H. H. Samuels.
1992.
Half-site spacing and orientation determines whether thyroid hormone and retinoic acid receptors and related factors bind to DNA response elements as monomers, homodimers, or heterodimers.
Mol. Endocrinol.
6:429-442[Abstract].
|
| 24.
|
Forman, B. M., and H. H. Samuels.
1990.
Interactions among a subfamily of nuclear hormone receptors: the regulatory zipper model.
Mol. Endocrinol.
4:1293-1301[Abstract].
|
| 25.
|
Forman, B. M., and H. H. Samuels.
1991.
pEXPRESS: a family of expression vectors containing a single transcription unit active in prokaryotes, eukaryotes and in vitro.
Gene
105:9-15[Medline].
|
| 26.
|
Forman, B. M.,
C.-R. Yang,
M. Au,
J. Casanova,
J. Ghysdael, and H. H. Samuels.
1989.
A domain containing leucine zipper like motifs mediates novel in vivo interactions between the thyroid hormone and retinoic acid receptors.
Mol. Endocrinol.
3:1610-1626[Abstract].
|
| 27.
|
Forman, B. M.,
C.-R. Yang,
F. Stanley,
J. Casanova, and H. H. Samuels.
1988.
c-erbA protooncogenes mediate thyroid hormone-dependent and -independent regulation of the rat growth hormone and prolactin genes.
Mol. Endocrinol.
2:902-911[Abstract].
|
| 28.
|
Geffner, M. E.,
F. Su,
N. Ross,
J. M. Hershman,
C. V. Dop,
J. B. Menke,
E.-H. Hao,
R. K. Stanzak,
T. Eaton,
H. H. Samuels, and S. J. Usala.
1993.
An arginine to histidine mutation in codon 311 of the c-erbA gene results in a mutant thyroid hormone receptor which does not mediate a dominant negative phenotype.
J. Clin. Invest.
91:538-546.
|
| 29.
|
Guernsey, D. L., and P. B. Fisher.
1990.
Thyroid hormone and neoplastic transformation.
Crit. Rev. Oncog.
1:389-408[Medline].
|
| 30.
|
Hadzic, E.,
V. Desai-Yajnik,
E. Helmer,
S. Guo,
S. Wu,
N. Koudinova,
J. Casanova,
B. M. Raaka, and H. H. Samuels.
1995.
A 10-amino-acid sequence in the N-terminal A/B domain of thyroid hormone receptor is essential for transcriptional activation and interaction with the general transcription factor TFIIB.
Mol. Cell. Biol.
15:4507-4517[Abstract].
|
| 31.
|
Haines, D. S.,
J. E. Landers,
L. J. Engle, and D. L. George.
1994.
Physical and functional interaction between wild-type p53 and mdm2 proteins.
Mol. Cell. Biol.
14:1171-1178[Abstract/Free Full Text].
|
| 32.
|
Halperin, Y.,
M. I. Surks, and L. E. Shapiro.
1990.
L-Triiodothyronine (T3) regulates cellular growth rate, growth hormone production, and levels of nuclear T3 receptors via distinct dose-response ranges in cultured GC cells.
Endocrinology
126:2321-2326[Abstract].
|
| 33.
|
Haupt, Y.,
R. Maya,
A. Kazaz, and M. Oren.
1997.
Mdm2 promotes the rapid degradation of p53.
Nature
387:296-299[Medline].
|
| 34.
|
Hinds, P. W.,
C. A. Finlay,
R. S. Quartin,
S. J. Baker,
E. R. Fearon,
B. Vogelstein, and A. J. Levine.
1990.
Mutant p53 cDNAs from human colorectal carcinomas can cooperate with ras in transformation of primary rat cells: a comparison of the "hot spot" mutant phenotypes.
Cell Growth Differ.
1:571-580[Abstract].
|
| 35.
|
Hodin, R.,
M. A. Lazar,
B. I. Wintman,
D. S. Darling,
R. J. Koenig,
P. R. Larsen,
D. D. Moore, and W. W. Chin.
1989.
Identification of a thyroid hormone receptor that is pituitary-specific.
Science
244:76-79[Abstract/Free Full Text].
|
| 36.
|
Horowitz, Z. D.,
H. Sahnoun,
A. Pascual,
J. Casanova, and H. H. Samuels.
1988.
Analysis of photoaffinity label derivatives to probe thyroid hormone receptor in human fibroblasts, GH1 cells and soluble receptor preparations.
J. Biol. Chem.
263:6636-6642[Abstract/Free Full Text].
|
| 37.
|
Horowitz, Z. D.,
C.-R. Yang,
B. M. Forman,
J. Casanova, and H. H. Samuels.
1989.
Characterization of the domain structure of chick c-erbA by deletion mutation: in vitro translation and cell transfection studies.
Mol. Endocrinol.
3:148-156[Abstract].
|
| 38.
|
Juven, T.,
Y. Barak,
A. Zauberman,
D. L. George, and M. Oren.
1993.
Wild-type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene.
Oncogene
8:3411-3416[Medline].
|
| 39.
|
Ko, L. J., and C. Prives.
1996.
p53: puzzle and paradigm.
Genes Dev.
10:1054-1072[Free Full Text].
|
| 40.
|
Kubbutat, M. H.,
S. N. Jones, and K. H. Vousden.
1997.
Regulation of p53 stability by Mdm2.
Nature
387:299-303[Medline].
|
| 41.
|
Landanyl, M.,
C. Cha,
R. Lewis,
S. C. Jhanwar,
A. G. Hacos, and J. H. Healy.
1993.
MDM2 gene amplification in metastatic osteosarcoma.
Cancer Res.
53:16-18[Abstract/Free Full Text].
|
| 42.
|
Landers, J. E.,
D. S. Haines,
J. F. Strauss III, and D. L. George.
1994.
Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells.
Oncogene
9:2745-2750[Medline].
|
| 43.
|
Lazar, M. A.
1993.
Thyroid hormone receptors: multiple forms, multiple possibilities.
Endocr. Rev.
14:184-193[Medline].
|
| 44.
|
Leveillard, T., and B. Wasylyk.
1997.
The MDM2 C-terminal region binds to TAFII250 and is required for MDM2 regulation of the cyclin A promoter.
J. Biol. Chem.
272:30651-30661[Abstract/Free Full Text].
|
| 45.
|
Marks, M. S.,
B.-Z. Levi,
J. H. Segars,
P. H. Driggers,
S. Hirschfeld,
T. Nagata,
E. Appella, and K. Ozato.
1992.
H-2RIIBP expressed from a baculovirus vector binds to multiple hormone response elements.
Mol. Endocrinol.
6:219-230[Abstract].
|
| 46.
|
Martin, K.,
D. Trouche,
C. Hagemeler,
T. S. Sorensen,
N. B. L. Thangue, and T. Kouzarides.
1995.
Stimulation of E2F1/DP1 transcriptional activity by mdm2 oncoprotein.
Nature
375:691-694[Medline].
|
| 47.
|
Momand, J.,
G. P. Zambetti,
D. C. Olson,
D. George, and A. J. Levine.
1992.
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.
Cell
69:1237-1245[Medline].
|
| 48.
|
Naar, A. M.,
J.-M. Boutin,
S. M. Lipkin,
V. C. Yu,
J. M. Holloway,
C. K. Glass, and M. G. Rosenfeld.
1991.
The orientation and spacing of core DNA-binding motifs dictate selective transcriptional responses to three nuclear receptors.
Cell
65:1267-1279[Medline].
|
| 49.
|
Oliner, J. D.,
K. W. Kinzler,
P. S. Meltzer,
D. George, and B. Vogelstein.
1992.
Amplification of a gene encoding a p53-associated protein in human sarcomas.
Nature
358:80-83[Medline].
|
| 50.
|
Olson, D.,
V. Marechal,
J. Momand,
J. Chen,
C. Romocki, and A. J. Levine.
1993.
Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes.
Oncogene
8:2353-2360[Medline].
|
| 51.
|
Qi, J.-S.,
V. Desai-Yajnik,
M. E. Greene,
B. M. Raaka, and H. H. Samuels.
1995.
The ligand-binding domains of the thyroid hormone/retinoid receptor gene subfamily function in vivo to mediate heterodimerization, gene silencing, and transactivation.
Mol. Cell. Biol.
15:1817-1825[Abstract].
|
| 52.
|
Qi, J.-S.,
V. Desai-Yajnik,
Y. Yuan, and H. H. Samuels.
1997.
Constitutive activation of gene expression by thyroid hormone receptor results from reversal of p53-mediated repression.
Mol. Cell. Biol.
17:7195-7207[Abstract].
|
| 53.
|
Samuels, H. H.,
B. M. Forman,
Z. D. Horowitz, and Z.-S. Ye.
1988.
Regulation of gene expression by thyroid hormone.
J. Clin. Invest.
81:957-967.
|
| 54.
|
Sap, J.,
L. deMagistris,
H. Stunnenberg, and B. Vennstrom.
1990.
A major thyroid hormone response element in the third intron of the rat growth hormone gene.
EMBO J.
9:887-896[Medline].
|
| 55.
|
Sap, J.,
A. Munoz,
J. Schmitt,
H. Stunnenberg, and B. Vennstrom.
1989.
Repression of transcription mediated at a thyroid hormone response element by the v-erb-A oncogene product.
Nature
340:242-244[Medline].
|
| 56.
|
Scheffner, M.,
B. A. Werness,
J. M. Huibregtse,
A. J. Levine, and P. M. Howley.
1990.
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.
Cell
61:1129-1136.
|
| 57.
|
Selmi, S., and H. H. Samuels.
1991.
Thyroid hormone receptor/c-erbA and v-erbA: a single amino acid difference in the C-terminal region influences dominant negative activity and receptor dimer formation.
J. Biol. Chem.
266:11589-11593[Abstract/Free Full Text].
|
| 58.
|
Shaulian, E.,
D. Resnitzky,
O. Shifman,
G. Blandino,
A. Amsterdam,
A. Yayon, and M. Oren.
1997.
Induction of Mdm2 and enhancement of cell survival by bFGF.
Oncogene
15:2717-2725[Medline].
|
| 59.
|
Soussi, T.,
C. C. deFromentel, and P. May.
1990.
Structural aspects of the p53 protein in relation to gene evolution.
Oncogene
5:945-952[Medline].
|
| 60.
|
Sturzbecher, H. W.,
R. Brain,
C. Addison,
K. Rudge,
M. Remm,
M. Grimaldi,
E. Keenan, and J. R. Jenkins.
1992.
A C-terminal -helix plus basic region motif is the major structural determinant of p53 tetramerization.
Oncogene
7:1513-1523[Medline].
|
| 61.
|
Subler, M. A.,
D. W. Martin, and S. Deb.
1994.
Overlapping domains on the p53 protein regulate its transcriptional activation and repression functions.
Oncogene
9:1351-1359[Medline].
|
| 62.
|
Umesono, K., and R. M. Evans.
1989.
Determinants of target gene specificity for steroid/thyroid hormone receptors.
Cell
57:1139-1146[Medline].
|
| 63.
|
Umesono, K.,
V. Giguere,
C. K. Glass,
M. G. Rosenfeld, and R. M. Evans.
1988.
Retinoic acid and thyroid hormone induce gene expression through a common responsive element.
Nature
336:262-265[Medline].
|
| 64.
|
Umesono, K.,
K. K. Murakami,
C. C. Thompson, and R. M. Evans.
1991.
Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D receptors.
Cell
65:1255-1266[Medline].
|
| 65.
|
Wang, L.-H.,
S. Y. Tsai,
R. G. Cook,
W. G. Beattle,
M.-J. Tsai, and B. W. O'Malley.
1989.
COUP transcription factor is a member of the steroid receptor superfamily.
Nature
340:163-166[Medline].
|
| 66.
|
Wang, Y.,
M. Reed,
P. Wang,
J. E. Stenger,
G. Mayr,
M. E. Anderson,
J. F. Schwedes, and P. Tegtmeyer.
1993.
p53 domains: identification and characterization of two autonomous DNA-binding regions.
Genes Dev.
7:2575-2586[Abstract/Free Full Text].
|
| 67.
|
Wu, X.,
J. H. Bayle,
D. Olson, and A. J. Levine.
1993.
The p53-mdm-2 autoregulatory feedback loop.
Genes Dev.
7:1126-1132[Abstract/Free Full Text].
|
| 68.
|
Xiao, Z. X.,
J. Chen,
A. J. Levine,
N. Modjtahedi,
J. Xing,
W. R. Sellers, and D. M. Livingston.
1995.
Interaction between the retinoblastoma protein and oncoprotein mdm2.
Nature
375:694-697[Medline].
|
| 69.
|
Zambetti, G. P.,
J. Bargonetti,
K. Walker,
C. Prives, and A. J. Levine.
1992.
Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element.
Genes Dev.
6:1143-1152[Abstract/Free Full Text].
|
| 70.
|
Zauberman, A.,
D. Flusberg,
V. Haupt,
Y. Barak, and M. Oren.
1995.
A functional p53-responsive intronic promoter is contained within the human mdm2 gene.
Nucleic Acids Res.
23:2584-2592[Abstract/Free Full Text].
|